Supernus (SUPN) soars 40% after it receives tentative FDA approval for its Trokendi XR treatment...

|About: Supernus Pharmaceuticals,... (SUPN)|By:, SA News Editor

Supernus (SUPN) soars 40% after it receives tentative FDA approval for its Trokendi XR treatment for epilepsy. Final authorization is conditional on Supernus resolving a marketing exclusivity issue regarding a specific pediatric population. The FDA also denies a Citizen's Petition filed in 2011 by Upsher Smith Labs related to its NDA on Trokendi XR.